Shares of Heat Biologics Inc (NASDAQ:HTBX) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price objective of $11.17 for the company and are expecting that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 120 out of 255 based on the ratings given to its competitors.

Several analysts have recently weighed in on the stock. Eurobank EFG assumed coverage on shares of Heat Biologics in a research report on Monday, July 9th. They set a “buy” rating and a $11.00 price objective on the stock. HC Wainwright assumed coverage on shares of Heat Biologics in a research report on Tuesday, June 26th. They set a “buy” rating and a $6.00 price objective on the stock. Brookline Cap M restated a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st. Finally, ValuEngine raised shares of Heat Biologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of Heat Biologics traded down $0.01, hitting $2.06, on Friday, MarketBeat reports. 132,701 shares of the company traded hands, compared to its average volume of 218,419. Heat Biologics has a 12-month low of $1.09 and a 12-month high of $7.90.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.05). The company had revenue of $0.75 million for the quarter. Heat Biologics had a negative net margin of 543.30% and a negative return on equity of 182.19%. equities analysts forecast that Heat Biologics will post -0.68 earnings per share for the current year.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.